NCT02182310View on ClinicalTrials.gov

Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

October 31, 2008

Conditions
Healthy
Interventions
DRUG

BI 201335 low dose

DRUG

BI 201335 placebo

DRUG

Moxifloxacin

DRUG

BI 201335 high dose

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY